186 related articles for article (PubMed ID: 22426694)
1. Simultaneous TLR2 inhibition and TLR9 activation synergistically suppress tumor metastasis in mice.
Yan J; Hua F; Liu HZ; Yang HZ; Hu ZW
Acta Pharmacol Sin; 2012 Apr; 33(4):503-12. PubMed ID: 22426694
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor.
Yao Y; Li J; Qu K; Wang Y; Wang Z; Lu W; Yu Y; Wang L
Cancer Immunol Immunother; 2023 May; 72(5):1103-1120. PubMed ID: 36326892
[TBL] [Abstract][Full Text] [Related]
3. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
[TBL] [Abstract][Full Text] [Related]
4. Blocking TLR2 activity attenuates pulmonary metastases of tumor.
Yang HZ; Cui B; Liu HZ; Mi S; Yan J; Yan HM; Hua F; Lin H; Cai WF; Xie WJ; Lv XX; Wang XX; Xin BM; Zhan QM; Hu ZW
PLoS One; 2009 Aug; 4(8):e6520. PubMed ID: 19654875
[TBL] [Abstract][Full Text] [Related]
5. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
6. A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
Jia H; Guo J; Wang P; Sun K; Chen J; Ren W; Wei T; Yang Y; Li J; Liu X; Li R; Zhong J; Wang M; Tian Z; Feng Z; Zhao T
Int Immunopharmacol; 2020 Jun; 83():106397. PubMed ID: 32220805
[TBL] [Abstract][Full Text] [Related]
7. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.
Sfondrini L; Sommariva M; Tortoreto M; Meini A; Piconese S; Calvaruso M; Van Rooijen N; Bonecchi R; Zaffaroni N; Colombo MP; Tagliabue E; Balsari A
Int J Cancer; 2013 Jul; 133(2):383-93. PubMed ID: 23319306
[TBL] [Abstract][Full Text] [Related]
9. TLR ligands in the local treatment of established intracerebral murine gliomas.
Grauer OM; Molling JW; Bennink E; Toonen LW; Sutmuller RP; Nierkens S; Adema GJ
J Immunol; 2008 Nov; 181(10):6720-9. PubMed ID: 18981089
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of pulmonary immune responses by the TLR2/6 agonist MALP-2 and effect on melanoma metastasis to the lung.
Schill T; Schön MP; Pletz N; Emmert S; Schön M
Exp Dermatol; 2012 Feb; 21(2):91-8. PubMed ID: 22044500
[TBL] [Abstract][Full Text] [Related]
11. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
Jordan M; Waxman DJ
Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
[TBL] [Abstract][Full Text] [Related]
12. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
13. Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.
Corogeanu D; Zaki K; Beavil AJ; Arnold JN; Diebold SS
PLoS One; 2023; 18(3):e0282831. PubMed ID: 36913398
[TBL] [Abstract][Full Text] [Related]
14. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy.
Chang LS; Leng CH; Yeh YC; Wu CC; Chen HW; Huang HM; Liu SJ
Mol Cancer; 2014 Mar; 13():60. PubMed ID: 24642245
[TBL] [Abstract][Full Text] [Related]
16. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma.
Sorrentino R; Morello S; Forte G; Montinaro A; De Vita G; Luciano A; Palma G; Arra C; Maiolino P; Adcock IM; Pinto A
Am J Respir Crit Care Med; 2011 May; 183(10):1369-79. PubMed ID: 21278302
[TBL] [Abstract][Full Text] [Related]
17. Successful immunotherapy of murine melanoma metastases with 7-thia-8-oxoguanosine.
Sharma BS; Balazs L; Jin A; Jolley WB; Robins RK
Clin Exp Metastasis; 1991; 9(5):429-39. PubMed ID: 1914279
[TBL] [Abstract][Full Text] [Related]
18. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.
Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD
Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651
[TBL] [Abstract][Full Text] [Related]
19. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis.
Ren T; Wen ZK; Liu ZM; Liang YJ; Guo ZL; Xu L
Cancer Biol Ther; 2007 Nov; 6(11):1704-9. PubMed ID: 17986857
[TBL] [Abstract][Full Text] [Related]
20. Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10.
de Melo FM; Braga CJ; Pereira FV; Maricato JT; Origassa CS; Souza MF; Melo AC; Silva P; Tomaz SL; Gimenes KP; Scutti JA; Juliano MA; Zamboni DS; Câmara NO; Travassos LR; Ferreira LC; Rodrigues EG
Immunol Cell Biol; 2015 Jan; 93(1):86-98. PubMed ID: 25223833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
